Functional and mechanistic studies on the toxicity of deoxyguanosine for the in vitro proliferation and differentiation of human peripheral blood B lymphocytes

Deoxyguanosine (dGuo) has been implicated as the toxic metabolite causing a severe impairment of cellular immunity in children with a genetic deficiency of purine nucleoside phosphorylase (PNP). In peripheral blood T cells of normal donors both the pathway which leads to phosphorylation of dGuo (ultimately resulting in deoxyguanosine triphosphate, dGTP) and the salvage pathway which starts with degradation of dGuo by PNP (resulting in the formation of guanosine triphosphate, GTP) contribute to the inhibition of proliferation. In normal peripheral blood B cells, addition of dGuo leads to an inhibition of proliferation and differentiation. The concentrations of dGuo needed to cause a 50% inhibition are equivalent for peripheral blood T cells and B cells. Inhibition of B cell differentiation can be observed at the level of intracytoplasmic as well as secreted Ig and concerns all Ig isotypes. The early phase of B cell activation which takes place during a 24-h preculture with formalinized Cowan I Staphylococci is not affected by dGuo; it is not until proliferation and differentiation of B cells, brought about by culturing in the presence of crude concanavalin A supernatant, occurs that inhibitory effects of dGuo become evident. Addition of dGuo to B cell cultures results in an intracellular accumulation of GTP and dGTP. Addition of 8-aminoguanosine, a PNP inhibitor, next to dGuo, completely prevents the dGuo-mediated inhibition. Under these circumstances the dGuo-mediated increase in intracellular GTP is abrogated while dGTP accumulation still occurs. This indicates that the inhibitory effect of dGuo on the proliferation and differentiation of peripheral blood B lymphocytes of normal donors is independent of dGTP accumulation.     

Two-step separation of human peripheral blood monocytes on discontinuous density gradients of colloidal silica-polyvinylpyrrolidinone.

Normal human peripheral blood monocytes were purified by a two-step separation. The first step, the standard Ficoll--Hypaque (F--H) buoyant density centrifugation, yielded mainly mononuclear cells, of which 24 +/- 9% were monocytes. Isopycnic centrifugation on discontinuous gradients of colloidal silica polyvinylpyrrolidinone (CS-PVP) further separated these mononuclear cells. The density interface between 1.070 and 1.060 g/ml yielded 82 +/- 7% monocytes, 5 +/- 4% granulocytes and 13 +/- 8% lymphocytes. Sixty-six percent of the monocytes obtained after F--H separation were recovered in this layer. The monocytes were intact and viable and retained their ability to phagocytose and kill Candida pseudotropicalis and to spread on glass coverslips. Motility (both random and towards a chemoattractant) was retained but was quantitatively less than after F--H separation alone. The relative purity of the monocyte population allowed assessment of major histocompatibility surface antigens by serotyping. This confirmed the presence of HLA and Ia-like antigens on monocytes.     

Bone matrix-directed chondrogenesis of muscle in vitro

Bone matrix is the largely collagenous residue of demineralized bone. Experimental data demonstrate that a substance, which is acid-stable during demineralization, occurs as a part of bone matrix, and that it is capable of stimulating the redifferentiation of skeletal muscle into cartilage. Reproducibility of redifferentiation is high and all cells derived from embryonic mesoderm appear competent to yield cartilage. This effect is highly significant to the developmental biology of musculoskeletal tissues, as muscle and cartilage arise from a similar embryonic origin. With regard to the embryonic limb as a model system, it appears that both muscle and cartilage progenitor cells do not have rigidly-defined developmental programs, and that this is a result of their origin from a common pool of embryonic mesoderm. This pool originates as embryonic mesenchyme long before any evidence of limb development can be detected. It is proposed that the active component of bone matrix, termed "bone morphogenetic protein (BMP)," acts upon a tissue whose developmental program is not stabilized, or has been experimentally destabilized (by injury), to augment and sustain syntheses of cartilage extracellular matrix. The use of bone matrix, and active substances derived from it, suggests that differentiation is not irreversible. Hard tissue growth and repair may occur via recruitment of competent responding cells from a variety of nonchondrogenic sources, provided that the extracellular milieu (i.e., presence of BMP) is supportive.